245 related articles for article (PubMed ID: 28058491)
1. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
Hiller JK; Schmoor C; Gaidzik VI; Schmidt-Salzmann C; Yalcin A; Abdelkarim M; Blagitko-Dorfs N; Döhner K; Bullinger L; Duyster J; Lübbert M; Hackanson B
Ann Hematol; 2017 Apr; 96(4):559-565. PubMed ID: 28058491
[TBL] [Abstract][Full Text] [Related]
2. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
[TBL] [Abstract][Full Text] [Related]
3. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Thol F; Damm F; Lüdeking A; Winschel C; Wagner K; Morgan M; Yun H; Göhring G; Schlegelberger B; Hoelzer D; Lübbert M; Kanz L; Fiedler W; Kirchner H; Heil G; Krauter J; Ganser A; Heuser M
J Clin Oncol; 2011 Jul; 29(21):2889-96. PubMed ID: 21670448
[TBL] [Abstract][Full Text] [Related]
4. DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome.
El Ghannam D; Taalab MM; Ghazy HF; Eneen AF
Blood Cells Mol Dis; 2014; 53(1-2):61-6. PubMed ID: 24512939
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
[TBL] [Abstract][Full Text] [Related]
7. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Xu Q; Li Y; Jing Y; Lv N; Wang L; Li Y; Yu L
Int J Cancer; 2020 Mar; 146(5):1457-1467. PubMed ID: 31344264
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
[TBL] [Abstract][Full Text] [Related]
12. DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia.
Sehgal AR; Gimotty PA; Zhao J; Hsu JM; Daber R; Morrissette JD; Luger S; Loren AW; Carroll M
Clin Cancer Res; 2015 Apr; 21(7):1614-20. PubMed ID: 25609058
[TBL] [Abstract][Full Text] [Related]
13. The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Demolis P; Béhanzin E; Moreau A; Hudson I; Flores B; Stemplewski H; Salmonson T; Gisselbrecht C; Bowen D; Pignatti F
Oncologist; 2016 Jun; 21(6):692-700. PubMed ID: 27091416
[TBL] [Abstract][Full Text] [Related]
14. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
[TBL] [Abstract][Full Text] [Related]
15. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients.
Shivarov V; Gueorguieva R; Stoimenov A; Tiu R
Leuk Res; 2013 Nov; 37(11):1445-50. PubMed ID: 23962568
[TBL] [Abstract][Full Text] [Related]
16. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
17. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Quintás-Cardama A; Ravandi F; Liu-Dumlao T; Brandt M; Faderl S; Pierce S; Borthakur G; Garcia-Manero G; Cortes J; Kantarjian H
Blood; 2012 Dec; 120(24):4840-5. PubMed ID: 23071272
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia.
Ibrahem L; Mahfouz R; Elhelw L; Abdsalam EM; Soliman R
Blood Cells Mol Dis; 2015 Jan; 54(1):84-9. PubMed ID: 25172541
[TBL] [Abstract][Full Text] [Related]
20. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.
Ribeiro AF; Pratcorona M; Erpelinck-Verschueren C; Rockova V; Sanders M; Abbas S; Figueroa ME; Zeilemaker A; Melnick A; Löwenberg B; Valk PJ; Delwel R
Blood; 2012 Jun; 119(24):5824-31. PubMed ID: 22490330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
